香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本通告全部或任何部分內容而產生或因倚賴該等內容而引致之任 何 損 失 承 擔 任 何 責 任。 二零二五年第一次H股類別股東會通告 茲通告 南 京 熊 猫 電 子 股 份 有 限 公 司（「本公司」）謹 定 於 二 零 二 五 年 十 二 月 四 日（星 期 四）緊 接 本 公 司 二 零 二 五 年 第 二 次 臨 時 股 東 大 會 及 本 公 司 二零二五年第一次A股 類 別 股 東 會 結 束 後 在 中 華 人 民 共 和 國（「中 國」）南 京市經天路7號會議室舉行二零二五年第一次H股 類 別 股 東 會（「H股 類 別股東會」），藉 以 審 議 並 酌 情 通 過 下 列 決 議 案。有 關 決 議 案 的 詳 情，請 參閱本公司日期為二零二五年十一月十二日的通函。除文義另有所指外， 本 通 告 所 用 詞 彙 與 該 通 函 所 界 定 者 具 有 相 同 涵 義。 承董事會命 南京熊猫電子股份有限公司 夏德傳 董 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本通告全部或任何部分內容而產生或因倚賴該等內容而引致之任 何 損 失 承 擔 任 何 責 任。 二零二五年第二次臨時股東大會通告 茲通告 南京熊猫電子股份有限公司（「本公司」）謹定於二零二五年 十 二 月 四 日（星 期 四）下午二時三十分在中華人民共和國（「中 國」）南京市經天 路7號會議室舉行二零二五年第二次臨時股東大會（「臨時股東大會」）， 藉 以 審 議 並 酌 情 通 過 下 列 決 議 案。有 關 決 議 案 的 詳 情，請 參 閱 本 公 司 日 期為二零二五年十一月 十 二 日 的 通 函。除 文 義 另 有 所 指 外，本 通 告 所 用 詞 彙 與 該 通 函 所 界 定 者 具 有 相 同 涵 義。 特別決議案 承董事會命 南京熊猫電子股份有限公司 夏德傳 董事長 1. 審議批准《關 於 修 改〈公司章程〉部分條款》的 議 案，授 權 公 司 管 理 層 處理修改《公司章程》部分條款的具體事宜 2. 審議批准 ...

证券代码：600775 证券简称：南京熊猫 公告编号：2025-030 南京熊猫电子股份有限公司 关于召开2025年第二次临时股东大会、2025 年第一次 A 股 类别股东会及 2025 年第一次 H 股类别股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 4 日 14 点 30 分 召开地点：南京市经天路 7 号公司会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 4 日 至2025 年 12 月 4 日 一、召开会议的基本情况 (一) 股东大会类型和届次 2025年第二次临时股东大会、2025 年第一次 A 股类别股东会及 2025 年第一次 H 股类别股东会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合 的方式 采用上海证券交易所网络投票系统，通过交易系统投票 ...

证券代码：600775 证券简称：南京熊猫 公告编号：临 2025-031 南京熊猫电子股份有限公司 关于调整 2025 年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本议案已经公司董事会审议通过，无需提交股东大会审议。 调整 2025 年度日常关联交易预计额度对上市公司的影响：调整预计额度所 涉及的关联交易，有利于公司生产和经营的稳定，遵循公平、公允的原则，按照 相关规定履行了审批程序，符合公司及全体股东的整体利益，不存在损害公司及 其股东尤其是中小股东利益的情况。本次调整日常关联交易预计额度的金额，乃 依据业务发展及实际经营情况，调整后的预计额度符合公司业务发展的实际情况。 该项日常关联交易将于日常业务过程中按正常商业条款进行，未影响公司的独立 性，公司主要业务不存在较大依赖关联人的情况。 一、日常关联交易基本情况 南京熊猫电子股份有限公司（以下简称"公司"）于 2025 年 2 月 28 日召开 第十一届董事会临时会议，审议通过了《2025 年度日常关联交易》的议案，同 ...

南京熊猫电子股份有限公司 2025 年第二次临时股东大会 2025 年第一次 A 股类别股东会 2025 年第一次 H 股类别股东会 会 议 资 料 2025 年 11 月 1 会议资料目录 | 会议资料目录 2 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 年第二次临时股东大会、2025 股类别股 | 2025 | 年第一次 | A | 股类别股东会、2025 | 年第一次 | H | | 东会会议须知 3 | | | | | | | | 年第二次临时股东大会、2025 股类别股 | 2025 | 年第一次 | A | 股类别股东会、2025 | 年第一次 | H | | 东会表决说明 5 | | | | | | | | 年第二次临时股东大会、2025 股类别股 | 2025 | 年第一次 | A | 股类别股东会、2025 | 年第一次 | H | | 东会会议议程 7 | | | | | | | | 年第二次临时股东大会会议议案…………………………………………………..……….9 | 2025 | | | | | | | 议案一： ...

Core Viewpoint - The brain-computer interface (BCI) concept stocks in the Hong Kong market have shown strong performance, driven by the advancement of a domestically developed implantable wireless BCI system entering a special review process by the National Medical Products Administration (NMPA) in China, marking a significant step in the commercialization of this technology [1][2]. Group 1: Market Performance - Brain动极光-B has increased by over 9%, with a latest price of 6.960 and a total market capitalization of 8.813 billion [2] - 微创脑科学 has risen by over 4%, with a latest price of 11.880 and a total market capitalization of 6.843 billion [2] - 南京熊猫电子股份 has gained nearly 3%, with a latest price of 5.140 and a total market capitalization of 4.697 billion [2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive BCI product to enter the "green channel" for innovative medical devices in China, indicating a key transition from clinical validation to market access in this cutting-edge technology field [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing a significant rise, driven by advancements in technology and supportive regulatory developments in China [1] Group 1: Market Performance - Brain-machine concept stocks have collectively surged, with notable increases: Brainhole Aurora (06681) up 8.49% to HKD 6.9, Nanjing Panda Electronics (00553) up 3.2% to HKD 5.16, and Microneuroscience (02172) up 4.39% to HKD 11.9 [1] Group 2: Regulatory Developments - On November 11, Shanghai Ladder Medical Technology Co., Ltd.'s "implantable wireless brain-machine interface system" entered the special review process for innovative medical devices by the National Medical Products Administration (NMPA), marking it as the first invasive brain-machine interface product to enter this "green channel" in China [1] - The NMPA has also released the YY/T 1987—2025 standard for medical devices utilizing brain-machine interface technology, indicating a formalization of industry standards [1] Group 3: Industry Outlook - Dongwu Securities expresses optimism regarding the domestic policy support and accelerated clinical and commercial progress in the brain-machine interface industry [1] - Huafu Securities notes that advancements in brain science, artificial intelligence, medicine, cognitive neuroscience, and psychology are enriching the scope of brain-machine interfaces, highlighting multiple advantages for the development of this industry in China [1]

Core Insights - The brain-computer interface (BCI) sector in China is experiencing significant advancements, with the first invasive BCI product entering the special review process by the National Medical Products Administration, marking a critical step towards market approval [1] - The Chinese government is actively promoting the BCI industry through various policies and standards, including the release of the first technical standard for BCI medical devices [1][2] - Clinical practices for BCIs in China are accelerating, with several hospitals initiating clinical applications and trials, positioning China as the second country globally to enter the clinical trial phase for invasive BCIs [3] Industry Developments - The BCI industry is expected to achieve key technological breakthroughs by 2027, establishing an advanced technical, industrial, and standard system, with a goal of nurturing globally influential companies by 2030 [2] - The BCI market is projected to grow significantly, with estimates indicating a market size of approximately $2.62 billion in 2024, reaching $2.94 billion by 2025, and potentially growing to $12.4 billion by 2034 [4] Clinical and Commercial Progress - Major hospitals in China are launching BCI clinical applications, with initiatives such as the first BCI outpatient clinic in Central China and the establishment of specialized clinical wards for BCI technology [3] - The development of BCI technology is seen as a beacon of hope for over 3 billion people suffering from neurological disorders globally [3] Investment Opportunities - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in BCI projects, with MicroPort achieving a significant market share in neuro-interventional medical devices in China [5] - Nanjing Panda Electronics is also engaged in BCI technology development, focusing on multimodal human-computer interaction systems [5]

Core Insights - The brain-computer interface (BCI) sector in China is experiencing significant advancements, with the first invasive wireless BCI system entering the special review process by the National Medical Products Administration, marking a critical step towards market approval [1] - The Chinese government is actively promoting the BCI industry through various policies and standards, including the release of the first technical standard for BCI medical devices, which provides a unified framework for development and regulation [1][2] - By 2027, breakthroughs in key BCI technologies are expected to establish an advanced technical, industrial, and standard system, with the goal of nurturing globally influential companies by 2030 [2] Industry Developments - Clinical practices for invasive BCIs in China are accelerating, with the country becoming the second globally to enter clinical trial phases after the United States [3] - Major hospitals are launching BCI clinical applications, indicating a shift from research-driven to clinically-driven development in the BCI field [3] - The global BCI market is projected to grow from approximately $2.62 billion in 2024 to $2.94 billion in 2025, with expectations to reach $12.4 billion by 2034 [4] Investment Opportunities - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in BCI projects, with MicroPort achieving a significant market share in neuro-interventional medical devices in China [5] - Heartway Medical is set to begin formal clinical trials for its invasive BCI project by the end of 2026, following successful animal testing [5] - Nanjing Panda Electronics is developing a multimodal human-computer interaction system based on BCI technology, indicating ongoing innovation in the sector [5]

Group 1 - Nanjing Panda (SH 600775) announced on November 7 that its 11th board meeting was held, where the proposal to cancel the supervisory board and abolish the "Supervisory Meeting Rules" was reviewed [1] - For the first half of 2025, Nanjing Panda's revenue composition was as follows: Smart City accounted for 53.7%, Electronic Manufacturing Products for 46.55%, and Intelligent Manufacturing for 4.08%, with inter-segment elimination at -4.33% [1] - As of the report date, Nanjing Panda's market capitalization was 11.1 billion yuan [1] Group 2 - The domestic art insurance market, valued at 4.8 billion yuan, faces challenges as insurers find pricing difficult, indicating a lack of optimism in the sector [1]